U.S. stock market midday update: Thermo Fisher Scientific up 9.24%, earnings report exceeds expectations + AI new product launch

U.S. Stock Market Midday Update

Thermo Fisher Scientific, up 9.24%. Based on recent news,

1. On July 23, Thermo Fisher Scientific reported growth in both revenue and profit for the second quarter. The company achieved a profit of $1.74 billion, with earnings per share of $4.68, and adjusted earnings per share of $6.03, exceeding analysts' expectations of $5.72. Revenue grew by 10% to $11.99 billion, surpassing analysts' forecast of $11.71 billion. This reflects strong performance in end markets and an increase in market share.

2. On July 23, Thermo Fisher Scientific opened a bioprocess design center in Massachusetts, aimed at expanding its business footprint and supporting more drug development and production. This move further enhances market confidence in the company's future growth.

3. On July 23, Thermo Fisher Scientific launched several new products, including a platform with AI analytics capabilities. The introduction of these new products demonstrates the company's progress in enhancing its capabilities, further driving the stock price upward. The overall performance of the medical technology industry is strong, with increased market confidence.

Top Stocks by Trading Volume in the Industry

Danaher, up 5.88%, with increased trading volume. Based on recent key news:

1. On July 21, Danaher reported its second-quarter financial results, with revenue and profit exceeding market expectations, and raised its full-year earnings per share guidance. Although delays in customer orders in the biopharmaceutical business impacted the stock price, which fell by 11.5%, the overall performance was strong, driving the stock price up.

2. On July 21, the company completed its acquisition of Masimo, which is expected to immediately enhance adjusted earnings per share. This move has strengthened market confidence in the company's future growth, positively impacting the stock price.

3. On July 21, Danaher raised its full-year earnings guidance, reflecting an improved outlook for core revenue growth in its life sciences business, as the recovery in related markets is faster than previously expected. This news boosted investor confidence, driving the stock price up. The life sciences industry is recovering, with significant capital inflow.

Medpace Holdings, up 15.56%. Based on recent key news:

1. On July 22, Medpace released its second-quarter financial results, with revenue increasing by 17.2% year-over-year to $707.3 million, and net profit reaching $121.4 million, driving the stock price up. Source: SEC announcement

2. On July 23, analysts maintained a neutral rating on Medpace, with a target price of $547, as the market remains cautious about its future growth. Source: Reuters

3. On July 23, management indicated a decrease in cancellation rates, driving net bookings growth, and the market is optimistic about the second half of the year. Source: Truist Securities The biotechnology industry has recently performed strongly, with significant capital inflow.

West Pharmaceutical Services, up 0.50%. Based on recent news,

1. On July 23, West Pharmaceutical Services announced its second-quarter financial report, with net sales of $872.3 million, exceeding market expectations of $838.6 million, and adjusted earnings per share of $2.37, also surpassing the expected $2.08. This strong financial performance drove the stock price up.

2. On July 23, the company raised its full-year net sales and adjusted earnings per share forecasts, expecting full-year net sales to be between $3.345 billion and $3.380 billion, and adjusted earnings per share to be between $8.85 and $9.05. This optimistic outlook further boosted market confidence.

3. On July 23, West Pharmaceutical Services announced that the strong growth of its high-value product components and biologics was the main factor driving performance improvement, expecting these products to achieve high double-digit growth for the year. The overall performance of the pharmaceutical industry is strong, supported by macroeconomic data.

Stocks Ranked Among the Top by Market Capitalization in the Industry

Agilent Technologies rose 3.95%. Based on recent key news:

1. On July 23, Agilent received EU certification for its PD-L1 IHC 22C3 pharmDx companion diagnostic for certain ovarian-related cancers. This label expansion supports Merck's KEYTRUDA use in the EU, driving the stock price up.

2. On July 22, Agilent adjusted the base BDR ratio of its BDR program in Brazil from 1:2 to 1:10, with a mandatory stock split providing an additional 4 BDRs for each shareholder holding 1 BDR, enhancing market confidence.

3. On July 21, Agilent reported a 5.5% increase in second-quarter revenue to $6.27 billion, exceeding expectations, with life sciences revenue growing 5.5% to $1.88 billion, surpassing expectations and boosting the stock price. The market is optimistic about technology stocks, with significant capital inflows